NMPA accepts clinical trial application for monkeypox vaccine
Share - WeChat

The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Domestic single-dose flu drug approved
- Water mahjong games cool visitors in Chongqing
- Sanya to host sixth Asian Beach Games in April
- Guangdong, Hong Kong and Macao to jointly hold entrepreneurship competition
- China approves rice-derived recombinant human albumin injection
- Hundreds attend 5th TCM Culture Festival in Tianjin